The purpose of this study is to investigate metastatic pancreatic cancer. This study investigates whether an investigational medication provides additional survival benefits compared to 5-FU in patients who have progressed after first-line treatment.
This study evaluates the effectiveness and safety of the investigational medication in comparison to 5-FU. It focuses on assessing whether the investigational medication can improve outcomes for patients with metastatic pancreatic cancer.
- Who can participate: Adults aged 18 and older with metastatic pancreatic cancer may participate. Participants must have progressed during or after gemcitabine treatment and have a good performance status. Certain health conditions, like significant heart disease or active infections, may exclude participation.
- Study details: Participants will receive either the investigational medication or 5-FU. The study will compare the effects of these treatments. A placebo is not used in this study.
How understandable was the trial content above?
Hard to understand
Easy to understand